Some Observations on Tax Policy for Pharmaceutical Research

Abstract

Internal Revenue Code and procedures concerning research expenditures in the pharmaceutical industry have very substantial effects on both the costs of drug products and the competitive position of US pharmaceutical companies which export drug products. The advantages to the community of tax credits for pharmaceutical research are reviewed in this paper and some of the practical difficulties in delineating how such credits should be qualified are discussed.